We are excited to announce positive data from the Phase 2 NAVAL-1 Trial and provide an update on the Nana-val clinical program. Listen to our NAVAL-1 update webcast here: https://lnkd.in/gbJ2MUmV Full news release can be found here: https://lnkd.in/ghAfBGbp
Viracta Therapeutics, Inc.
Biotechnology Research
Cardiff-by-the-Sea, California 3,663 followers
A precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients
Über uns
Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide.
- Website
-
http://www.viracta.com
External link for Viracta Therapeutics, Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Cardiff-by-the-Sea, California
- Typ
- Öffentliches Unternehmen
- Spezialitäten
- Lymphoproliferative Disorders, Immuno-Oncology, Gastric Cancer, Epstein-Barr Virus, and lymphoma
Standorte
-
Primäre
2533 S Coast Hwy 101
Cardiff-by-the-Sea, California 92007, US
Employees at Viracta Therapeutics, Inc.
Aktualisierungen
-
Viracta Therapeutics, Inc. reposted this
Today on #NationalCancerSurvivorsDay, we’re celebrating the resilience and strength of lymphoma survivors. The Lymphoma Research Foundation powers groundbreaking survivorship research and provides resources and support every step of the way, from the moment of diagnosis through treatment and beyond. Join us today to honor our community of survivors and thrivers: https://ow.ly/tSGf50S4qsn
-
-
We're supporting World Blood Cancer Day!
May 28 is World Blood Cancer Day! A day dedicated to global awareness and the fight against blood cancer! #Lymphoma is the most commonly occurring blood cancer and the third most common childhood cancer. One million people around the world are living with lymphoma today, yet many people are still unaware of lymphoma and that it is a life-threatening form of cancer. The symptoms of lymphoma are commonly seen in other less serious illnesses, such as the flu or other viral infections. These symptoms are often overlooked, but in cases of less serious illnesses they would not last very long. With lymphoma, these symptoms persist over time. Our best prevention strategy is Health Literacy on Lymphomas, identifying the signs & symptoms, and early referral. #WBCD is coordinated by DKMS UK
-
-
We are thrilled to announce that Mike Faerm has joined Viracta as our Chief Financial Officer. Mike is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking. Please join us in welcoming him to #TeamViracta! https://lnkd.in/eGRCzc6a
-
-
We are excited to announce positive topline Nana-val results from Stage 1 of the NAVAL-1 trial in patients with R/R EBV+ PTCL. Here are the key highlights: 🔹 Patients with R/R EBV+ PTCL have a very poor prognosis, worse than those with EBV- disease, yet there are presently no EBV-targeted treatment options available 🔹Patients in the Nana-val treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population. 🔹 Nana-val demonstrated substantially greater efficacy than nanatinostat monotherapy, further validating its ‘Kick and Kill’ mechanism of action. 🔹 Nana-val was generally well tolerated, most common treatment-related adverse events were primarily mild to moderate in severity, and generally manageable or reversible. Read the full press release: https://lnkd.in/gNviCGhz #viractatherapeutics #NAVAL1Trial #ebv #EBVPositivePTCL #PrecisionOncology #ClinicalTrialResults
-
-
Today marks the 60th anniversary of the discovery of the Epstein-Barr Virus (EBV), one of the most common viral infection in humans and the first virus to be identified as oncogenic in humans. In addition to cancer, EBV is also linked as a major driver of MS and other autoimmune diseases.
The virus that infects almost everyone, and its link to cancer and MS – podcast https://lnkd.in/eAiyTiqC
-
Viracta Therapeutics, Inc. reposted this
Epstein-Barr Virus at 60. The 1964 discovery of Epstein–Barr virus shed light on factors that contribute to human cancer. Subsequent studies set the stage for finding ways to diagnose and treat cancer, and revealed how immune defences control viral infection. #EBV #viruses #cancer #immunology #lymphoma #multiplesclerosis
Epstein–Barr virus at 60
nature.com